Close Menu

NEW YORK – LevitasBio, a Stanford spinout commercializing a cell purification and separation technology based on magnetic levitation, said on Wednesday that it has raised $18 million in a Series B financing round.

Thalys Medical Group led the round, joined by Series A lead investor Decheng Capital.

LevitasBio also said it would form a China-based joint venture with Thalys to further develop, manufacture, and distribute the firm's technology in that country.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.